Policy | April 09, 2026
India Pharma Conference 2026 to spotlight innovation, global partnerships in New Delhi
Discussions are likely to centre on how the country can move up the pharmaceutical value chain
Discussions are likely to centre on how the country can move up the pharmaceutical value chain
The acquisition complements Gilead’s existing oncology expertise and development infrastructure
TG4050 harnesses Transgene’s myvac platform and NEC’s AI-powered neoantigen prediction technology to tailor vaccines to each patient’s tumor
The new capital is expected to fund the company through 2029
Interchangeable biosimilars to Prolia and Xgeva target osteoporosis and cancer-related bone complications in a $5 billion U.S. market
Under the collaboration, Symeres will test Ambagon’s newly designed molecular glues using in vitro assays and mechanistic studies
The drug meets all primary endpoints across 608 patients in Europe and India, strengthening the company's biosimilars pipeline
EB-003 is Enveric’s lead neuroplastogen, a 5-HT2A / 5-HT1B dual-acting compound designed to promote neuroplastic changes
Move aligns global biologics identity under the Biocon Biologics brand
Safety was equally impressive. ENV-294 was well tolerated
Subscribe To Our Newsletter & Stay Updated
